Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 5, 2000, Pages 364-369

  Koistinen, Heikki A ^a,c   Dusserre, Eric ^b   Ebeling, Pertti ^a   Vallier, Paulette ^b   Koivisto, Veikko A ^a   Vidal, Hubert ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b INSERM   (France)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cardiovascular disease; Hyperinsulinemic clamp; Insulin resistance; Leptin; Obesity; Plasminogen activator inhibitor (PAI)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; TISSUE DISTRIBUTION;

EID: 0033759501     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-7560(2000)9999:9999<::AID-DMRR148>3.0.CO;2-C     Document Type: Article

References (31)

1. Plasminogen activator inhibitors
2. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
3. Diabetes and atherosclerosis: An epidemiologic view
4. Role of insulin resistance in human disease
5. Hyperinsulinemia as an independent risk factor for ischemic heart disease
6. Insulin stimulates the synthesis of plasminogen activator inhibitor I by the human hepatocellular cell line HepG2
7. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
8. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type I by insulin on soluble factors released from vascular smooth muscle cells
9. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
10. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
11. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects
12. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women
13. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
14. Glucose clamp technique: A method for quantifying insulin secretion and resistance
15. Athletes with IDDM exhibit impaired metabolic control and increased lipid utilization with no increase in insulin sensitivity
16. The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue
17. The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples
18. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: No alteration in adipose tissue of obese and NIDDM patients
19. Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean humans
20. The organization of the human plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family
21. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults
22. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
23. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo
24. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1)
25. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man
26. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity
27. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women. Modulation by cross-sex hormone administration
28. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
29. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
30. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL
31. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells